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ABSTRACT
Objective Imaging is recommended to support the 
clinical diagnoses of dementias, yet imaging research 
studies rarely have pathological confirmation of disease. 
This study aims to characterise patterns of brain volume 
loss in six primary pathologies compared with controls 
and to each other.
Methods One hundred and eighty-six patients with 
a clinical diagnosis of dementia and histopathological 
confirmation of underlying pathology, and 73 healthy 
controls were included in this study. Voxel-based 
morphometry, based on ante-mortem T1-weighted MRI, 
was used to identify cross-sectional group differences in 
brain volume.
Results Early-onset and late-onset Alzheimer’s disease 
exhibited different patterns of grey matter volume loss, 
with more extensive temporoparietal involvement in the 
early-onset group, and more focal medial temporal lobe 
loss in the late-onset group. The Presenilin-1 group had 
similar parietal involvement to the early-onset group with 
localised volume loss in the thalamus, medial temporal 
lobe and temporal neocortex. Lewy body pathology was 
associated with less extensive volume loss than the other 
pathologies, although precentral/postcentral gyri volume 
was reduced in comparison with other pathological 
groups. Tau and TDP43A pathologies demonstrated 
similar patterns of frontotemporal volume loss, although 
less extensive on the right in the 4-repeat-tau group, 
with greater parietal involvement in the TDP43A group. 
The TDP43C group demonstrated greater left anterior-
temporal involvement.
Conclusions Pathologically distinct dementias exhibit 
characteristic patterns of regional volume loss compared 
with controls and other dementias. Voxelwise differences 
identified in these cohorts highlight imaging signatures 
that may aid in the differentiation of dementia subtypes 
during life. The results of this study are available for 
further examination via NeuroVault (http:// neurovault. 
org/ collections/ ADHMHOPN/).
INTRODUCTION
Cerebral atrophy is a downstream effect of neuro-
degeneration,1 with detectable changes in early2 
and even presymptomatic3 disease stages. Patterns 
of cross-sectional atrophy are included as core 
or supporting features in many consensus diag-
nostic guidelines,4–8 and longitudinal atrophy rates 
are used as outcome measures in clinical trials.9 
While there is substantial evidence to support the 
use of patterns of brain volume loss to aid in the 
differential diagnosis of dementia,10 11 much of the 
evidence base is derived from patients with clinical 
diagnoses, which may be inaccurate in up to 30% 
of cases, even in specialist centres.12 Identifying 
patterns of atrophy that help to distinguish patho-
logical processes from each other (and from normal 
ageing), based on gold standard histopathology, 
may provide greater understanding of the ability 
of clinical imaging to predict dementia pathology 
and help to translate imaging features, identified 
through research, into clinically useful biomarkers.
To date, relatively few imaging studies using 
voxelwise approaches are based on cases with histo-
pathological confirmation of diagnosis, and those 
who have typically used small sample sizes. Further-
more, many studies have made comparisons only 
between people with dementia and healthy controls 
(see table 1 for a review of the literature), whereas 
in clinical practice, structural imaging is increasingly 
used to distinguish between the different patholog-
ical forms of dementia. Motivated by this clinical 
question, we performed a comprehensive compu-
tational analysis of brain volume loss in the largest 
series yet reported, including 186 individuals with 
a diagnosis of dementia during life and primary 
histopathological diagnosis of one of six patholo-
gies (Alzheimer’s disease (AD), dementia with Lewy 
bodies (DLB), 3-repeat-tau, 4-repeat-tau, TDP43A 
and TDP43C (transactive response DNA-binding 
protein 43)). The aim of this study was to identify 
patterns of atrophy that would not only differen-
tiate these primary neurodegenerative pathology 
groups from cognitively healthy control subjects 
but, critically, also from one another.
MATERIALS AND METHODS
Study population
Two hundred and fifteen people were identified with 
a usable T1-weighted MRI, a diagnosis of dementia 
during life and post-mortem (n=206) or biopsy 
(n=9) confirmation of the underlying pathology. 
Twenty-one individuals were excluded for having 
incomplete or inconclusive pathology, and eight 
individuals were excluded due to insufficient data 
to study them as a group (n=4 amyloid precursor 
protein mutation carriers, n=1 TDP43B, n=3 with 
fused in sarcoma pathology). A total of 186 indi-
viduals were included in the subsequent analysis: 
107 had a primary pathology diagnosis of AD (68 
early-onset (<65 years at disease onset), 29 late-
onset (≥65 years at disease onset), 10 presenilin-1 
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Table 1 Voxel-based morphometry studies in pathology-confirmed (or genetically confirmed) dementias
Study Year Defined pathologies
Pathology confirmed 
cases, n
Comparison with 
controls
Direct pathology 
comparison PubMed ID
Whitwell et al 2004 Tau-positive FTLD, tau-negative FTLD 9, 8 Yes No 16908994
Whitwell et al 2005 FTLD-U, Pick's, MAPT 9, 7, 5 Yes Yes 16157747
Josephs et al 2006 NA—various pathologies grouped by language 
impairment features
12 NA NA 16613895
Grossman et al 2007 Tau-positive FTLD, tau-negative FTLD, (frontal 
variant)-AD
5, 4, 3 Yes No 17998442
Josephs et al 2008a (aphasic)-AD, (aphasic)-FTLD-U, (typical)-AD 5, 5, 10 Yes Yes 18166704
Josephs et al 2008b PSP, CBD 13, 11 Yes No 17097770
Josephs et al 2008c Argyrophilic grain pathology 12 Yes No 17188783
Whitwell et al 2008 Braak stages III–VI 10, 13, 32, 27 Yes NA 18765650
Josephs et al 2009 NA—FTLD groups defined based on clinical 
features
11 NA NA 19884571
Pereira et al 2009 Tau-positive FTLD, FTLD-U 6, 9 Yes No 19433738
Hu et al 2010 NA—various pathologies grouped by language 
impairment features
8 NA NA 20713948
Josephs et al 2010 (CBS)-CBD, (CBS)-AD 6, 5 Yes Yes 20629131
Rohrer et al 2010a GRN, MAPT 9, 11 Yes Yes 20045477
Rohrer et al 2010b FTLD-TDP43 (types A–C and unspecified) 9, 5, 10, 4 Yes No 21172843
Whitwell et al 2010a (CBS)-TDP43, (CBS)-AD, (CBS)-CBD, (CBS)-PSP 5, 6, 7, 6 Yes Yes 21098403
Whitwell et al 2010b FTLD-TDP43 (types A–C) 22, 9, 11 Yes Yes 21172844
Lee et al 2011 CBD, (CBS)-AD, (CBS)-CBD, (CBS)-PSP, (CBS)-TDP, 
(CBS)-mixed
18, 9, 14, 5, 5, 5 Yes Yes 21823158
Rankin et al 2011 (bvFTD)-CBD, (bvFTD)-Pick's 5, 5 Yes Yes 21881831
Rohrer et al 2011 Pick's, MAPT, CBD, TDP43A, TDP43C 9, 6, 5, 6, 12 Yes No 21908872
Whitwell et al 2011a (typical)-AD, (atypical)-AD, FTLD 14, 14, 14 Yes Yes 19914744
Whitwell et al 2011b Pick's, CBD, TDP43A 5, 5, 5 Yes Yes 21556732
Boxer et al 2012 NA—FTLD and AD correlations with saccade 
parameters
37 NA NA 22491196
Hornberger et al 2012 (bvFTD)-FTLD, AD 19, 18 Yes No 23012333
Khan et al 2012 (slowly progressive bvFTD)-C9ORF72 2 Yes No 22399793
Mahoney et al 2012 C9ORF72, MAPT, GRN 11, 11, 8 Yes Yes 22366791
Whitwell et al 2012a NA—bvFTD groups defined based on frontal 
lobe symmetry
80 NA NA 22502999
Whitwell et al 2012b MAPT, GRN, C9ORF72, FTLD 25, 12, 19, 12 Yes Yes 22366795
Whitwell et al 2012c typical AD, hippocampal-sparing AD, limbic-
predominant AD
125, 19, 33 Yes Yes 22951070
Cash, Ridgway et al 2013 (presymptomatic)-familial AD, (symptomatic)-
familial AD
69, 50 Yes Yes 24049139
Caso et al 2013 Pick's 1 Yes No 22713404
Coon et al 2013 FTLD-MND 2 Yes No 22051030
Scahill et al 2013 APP, PSEN1 10, 18 Yes Yes 23380992
Toledo et al 2013 AD, AD+MTL, AD+DLB, AD+DLB+MTL 7, 5, 6, 4 No Yes 24252435
Josephs et al 2013a (typical)-AD, (lvPPA)-AD 20, 10 Yes No 23541297
Josephs et al 2013b CSTD-positive TDPC, CSTD-equivocal TDPC, 
CSTD-negative TDPC
2, 5, 5 Yes Yes 23358603
Murray et al 2013 NA—DLB groups defined by presence of REM 
sleep behaviour disorder
75 NA NA 24107861
Caso et al 2014 (nfvPPA)-tau, (nfvPPA)-TDP43 9, 2 Yes No 24353332
Henry et al 2014 TDP43C 1 Yes No 23171151
Josephs 2014 TDP43-positive AD, TDP43-negative AD 195, 147 Yes Yes 24659241
Nedelska et al 2015 DLB, DLB-AD, AD 20, 22, 30 Yes Yes 25128280
Ossenkoppele et al 2015 (behavioural/dysexecutive)-AD, (typical)-AD, 
(bvFTD)-FTLD
24, 17, 12, 8, 21 Yes Yes 26141491
Sala-Llonch et al 2015 Symptomatic-PSEN1, asymptomatic-PSEN1 11, 13 Yes No 25638532
Shingawa et al 2015 NA—C9ORF72 groups were defined based on 
the presence of delusions
17 NA NA 25342578
Parentheses indicate additional clinical features or diagnosis. The number of pathology cases is listed per defined pathology group.
AD, Alzheimer’s disease; APP, amyloid precursor protein mutation carriers; bvFTD, behavioural variant FTD; C9ORF72, chromosome 9 open reading frame 72 mutation carriers; CBD, 
corticobasal degeneration; CBS, corticobasal syndrome; CTSD, corticospinal tract degeneration;  DLB, dementia with Lewy bodies; FTD, frontotemporal dementia; FTLD, frontotemporal 
lobar degeneration; FTLD-MND, FTLD with motor neuron disease; FTLD-U, FTLD with ubiquitin-positive (tau-synuclein-negative and alpha-synuclein-negative) inclusions;  GRN, progranulin 
mutation carriers; MAPT, microtubule-associated protein tau mutation carriers; MTL, medial temporal lobe pathology; NA, not applicable; nfvPPA, non-fluent variant primary progressive 
aphasia; PSEN1 , presenilin-1 mutation carriers; PSP, progressive supranuclear palsy; TDP43, transactive response DNA-binding protein 43.
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mutation carriers), 25 with DLB, 11 with 3-repeat-tau, 17 
with 4-repeat-tau, 12 TDP43A, and 14 TDP43C. Pathological 
examination of brain tissue was carried out between 1997 and 
2015 according to standard histopathological processes and 
criteria in use at the time of assessment at one of four centres: 
the Queen Square Brain Bank, London; Kings College Hospital, 
London; VU Medical Centre, Amsterdam and Institute for 
Ageing and Health, Newcastle. The study included 73 cognitively 
normal control subjects (based on clinical diagnosis) who were 
recruited to various imaging studies that had been carried out 
at the Dementia Research Centre, London. Controls were sepa-
rated into younger (<65 years of age at the time of scan, n=33) 
and older (≥65 years of age at the time of scan, n=40) groups 
to better match the patient groups. All patients or their legal 
representatives consented, during life, to brain donation and use 
of their clinical data for research purposes at each of the partic-
ipating sites. Ethical approval for this retrospective study was 
obtained from the National Research Ethics Service Committee 
London-South East. Group demographics were compared using 
Kruskal-Wallis tests, with a significant result being followed by 
post hoc pairwise multiple comparisons testing using Dunn’s 
test. A subset of these subjects was included in earlier work 
focusing on visual rating scales.13 Data processing and analyses 
were performed using Python libraries NumPy 1.8.1 (http://
www. numpy. org/), SciPy 0.14.0 (https://www. scipy. org/ scipylib/ 
index. html) and Pandas 0.14.1 (http:// pandas. pydata. org/) on 
Python 2.7.6–64-bit.
MRI scanning
All individuals had T1-weighted volumetric MRI performed 
during life. As the data were collected retrospectively from 
multiple centres, the images were acquired on scanners from 
three different manufacturers (Philips, GE, Siemens) using a 
variety of different imaging protocols. Magnetic field strength 
varied between 1.0 T (n=15 scans), 1.5 T (n=201 scans) and 
3 T (n=43 scans).
Image analysis
Voxel-based morphometry (VBM) preprocessing and analysis 
was performed using SPM12b (Statistical Parametric Mapping, 
V.12b revision 5829; http://www. fil. ion. ucl. ac. uk/ spm) and 
Matlab V.R2012a (7.14.0.739–64-bit,  uk. mathworks. com/ prod-
ucts/ matlab/). Due to the variability in scanning parameters, an 
initial rigid registration to the Montreal Neurological Institute 
International Consortium for Brain Mapping 152 (ICBM152) 
template was performed using the Reg-Aladin tool from the 
NiftyReg package (https:// sourceforge. net/ projects/ niftyreg/) to 
provide a better starting point for the SPM preprocessing pipe-
line. Each registration was then checked and manually adjusted 
(if necessary) such that the anterior commissure was within a few 
millimetres of the origin and the orientation was within a few 
degrees of the ICBM152 template. Grey matter, white matter and 
cerebrospinal fluid (CSF) segmentations were obtained using the 
unified segmentation approach14 with default settings. A group 
average tissue probability map was generated through iterative 
alignment of the initial grey and white matter segmentations to 
an evolving estimate of their groupwise average using the Dartel 
toolbox.15 The initial grey and white matter segmentations were 
then warped using the Dartel transformations and modulated to 
account for local volume changes, then smoothed with a 6 mm 
full width at half maximum Gaussian kernel. Grey and white 
matter masks were created based on the optimal threshold of the 
group average segmentations using the automatic mask creation 
strategy in the SPM Masking toolbox (http:// www0. cs. ucl. ac. uk/ 
staff/ g. ridgway/ masking/).
The imaging data were assessed by applying the general linear 
model at the level of each voxel using all images (n=259) and 
modelling the following terms: a 10-level group factor (younger 
controls, older controls, early-onset AD, presenilin-1 muta-
tion carriers, late-onset AD, DLB, 3-repeat-tau, 4-repeat-tau, 
TDP43A and TDP43C); factors representing magnetic field 
strength, imaging site and sex; and covariates for age at the 
time of scanning and total intracranial volume (computed by 
summing up probabilistic voxel volumes in grey matter, white 
matter and CSF segmentations). The model was used to inves-
tigate the pairwise contrasts between the primary pathology 
groups, with the AD pathology group stratified by age at 
disease onset and genetic mutation status. The groups were also 
contrasted with age-matched controls (ie, older controls were 
contrasted with the late-onset AD and DLB groups; younger 
controls were contrasted with all other groups). Correction for 
multiple comparisons was made using random field theory (for 
peak height) to control the familywise error (FWE) rate at a 
significance level of p<0.001, or 0.05 in most cases, although 
some results are shown at an uncorrected level of p<0.001. 
Unthresholded effect size maps are also displayed to allow better 
characterisation of brain volume loss that did not reach statis-
tical significance.
RESULTS
Study population
Demographic details of the patients and control subjects are 
presented in table 2. As expected, the late-onset AD group and 
the DLB group were, on average, older than the other groups at 
disease onset, and therefore, at the time of scanning, although 
this did not reach statistical significance in all cases (see online 
supplementary table 1). Between-group testing of time from 
scan until death was statistically significant (p<0.05) with the 
DLB group having the shortest mean interval (3.7 years) and 
the TDP43C group with the longest mean interval (7.0 years); 
however, these differences did not survive multiple comparisons 
correction. There were no statistically significant differences in 
sex (p=0.05), disease duration (p=0.13), Mini-Mental State 
Examination within 12 months of scanning (p=0.24) or total 
intracranial volume (p=0.20) between the pathology groups.
Comparison with age-matched controls
Using a strict statistical threshold (p<0.001 FWE), significant 
differences in grey matter volume were found between each 
of the pathology groups and the appropriate age-matched 
control group (figure 1). The early-onset AD group demon-
strated a diffuse pattern of atrophy, predominantly affecting 
the parietal and temporal cortex, with some additional exten-
sion into the frontal lobes. The presenilin-1 subgroup had 
similar parietal extension with more localised volume loss in 
the thalamus, medial temporal lobe and temporal neocortex. 
Compared with older control subjects, the late-onset AD group 
had a more focal pattern of grey matter volume loss in the 
medial temporal lobes, particularly the hippocampi. The DLB 
group also demonstrated significant medial temporal lobe 
atrophy when compared with older controls; however, this was 
much less extensive than the changes seen in the AD group, 
affecting the amygdalae (bilaterally, although worse on the 
left), the region of the left choroid fissure and a very small 
region around the lateral superior temporal gyrus. Relaxing the 
statistical threshold to p <0.05 FWE (figure 2), further volume 
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differences were seen in the region of the right amygdala 
and choroid fissure; however, extension into other temporal 
lobe regions was confined to the left hemisphere. The fron-
totemporal lobar degeneration (FTLD)-tau groups had exten-
sive grey matter volume loss in the frontal lobe affecting the 
superior, middle and inferior frontal gyri, extending into 
the insula. However, the right hemisphere was less severely 
affected in the 4-repeat-tau group, whereas the 3-repeat-tau 
group showed greater extension into the anterior temporal 
lobes. The TDP43A group demonstrated a similar, more 
symmetrical pattern of frontal volume loss, with additional 
volume loss extending into parietal lobe regions. The thalamic 
region was significantly affected in all three FTLD pathologies 
(3-repeat-tau, 4-repeat-tau and TDP43A). The TDP43C group 
had a significant volume loss in the temporal lobe, particularly 
anteriorly and in the left hemisphere where it extended into 
the frontal piriform and insular cortex. The reverse contrast 
was also investigated in all groups but showed no statistically 
Table 2 Patient demographics
Younger
controls
Older
controls EOAD PSEN1 LOAD DLB 3R-tau 4R-tau TDP43A TDP43C
N 33 40 68 10 29 25 11 17 12 14
Sex (%male) 30 70 65 60 66 72 72 53 50 50
Age at onset (years) NA NA 55.3 (5.7) 39.6 (4.6) 71.7 (6.0) 67.1 (6.1) 57.2 (6.3) 61.4 (9.7) 58.2 (6.5) 61.6 (8.0)
Age at scan (years) 59.9 (4.8) 72.2 (5.2) 60.5 (6.2) 44.0 (4.2) 75.8 (5.7) 71.3 (6.0) 62.6 (6.2) 65.7 (9.3) 60.3 (7.7) 66.0 (6.6)
Disease duration
at scan (years)
NA NA 5.2 (2.9) 4.4 (2.3) 4.1 (2.1) 4.2 (2.9) 5.4 (2.1) 4.4 (2.4) 2.9 (2.4) 4.5 (3.0)
MMSE (×/30) NA NA 18 (7) 15 (6) 19 (5) 20 (5) 21 (7) 23 (5) 17 (8) 23 (6)
Time from scan
until death (years)
NA NA 5.8 (2.9) 4.2 (2.2) 5.7 (3.3) 3.7 (2.3) 6.0 (3.5) 4.8 (2.3) 5.2 (4.0) 7.0 (3.4)
TIV (mL) 1425 (121) 1531 (156) 1504 (155) 1440 (163) 1484 (136) 1530 (149) 1506 (164) 1517 (178) 1480 (133) 1483 (165)
1.5 T scans 79% 73% 77% 80% 86% 76% 91% 76% 50% 86%
3.0 T scans 21% 27% 13% 20% 7% 8% 9% 24% 33% 7%
Data are reported as mean (SD).
DLB, dementia with Lewy bodies; EOAD, early-onset Alzheimer's disease; LOAD, late-onset Alzheimer's disease; MMSE, Mini-Mental State Examination (within 12 months of 
scanning); NA, not applicable; PSEN1, presenilin-1 mutation carriers; TDP43, transactive response DNA-binding protein 43; TIV, total intracranial volume;
Figure 1 Grey matter volume differences based on pairwise comparison with the appropriate age-matched control group. All results are shown at a 
familywise error corrected significance level of p <0.001. Brain slices are displayed based on peak voxel location. DLB, dementia with Lewy bodies; EOAD, 
early-onset Alzheimer's disease; FTLD, frontotemporal lobar degeneration; L, left; LOAD, late-onset Alzheimer's disease; OC, older controls; R, right; YC, 
younger controls. 
group.bmj.com on June 23, 2017 - Published by http://jnnp.bmj.com/Downloaded from 
5Harper L, et al. J Neurol Neurosurg Psychiatry 2017;0:1–9. doi:10.1136/jnnp-2016-314978
Neurodegeneration
Figure 3 Grey matter volume differences based on pairwise comparison with the Alzheimer's disease pathology groups. The axial image slices are effect 
size maps and the label shown above each map indicates the group comparison. Text colour relates to image colour, with the coloured regions in the image 
representing greater volume loss in the associated group, and brain slices chosen to represent the most interesting findings. The statistical parametric map 
slices to the left and right of the effect size maps represent the forward and reverse contrasts associated with each group comparison, with brain slices 
displayed based on peak voxel location. Greater volume loss in the blue group is shown on the left, with the red group shown on the right statistical 
parametric map. DLB, dementia with Lewy bodies; EOAD, early-onset Alzheimer disease; FTLD, frontotemporal lobar degeneration; FWE, familywise error 
rate; L, left; LOAD, late-onset Alzheimer's disease; R, right; UNC, uncorrected (for multiple comparisons).
Figure 2 DLB versus older controls. Grey matter volume differences based on pairwise comparison between the DLB and older control groups. The 
statistical parametric map is shown on the left with brain slices displayed based on peak voxel location. Results are thresholded at a significance level 
of p<0.05 familywise error corrected. The axial effect size map is shown on the right, regions in blue represent greater volume loss in the DLB group. 
DLB, dementia with Lewy bodies; FWE, familywise error rate; L, left; OC, older controls; R, right.
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significant regions where volume loss was more pronounced in 
the control group.
Comparison between pathology groups
Differences in grey matter volume based on pairwise compari-
sons of each of the pathology groups are presented in figures 3 
and 4. The early-onset AD group had significant grey matter 
volume loss in parietal lobe regions (p<0.05 FWE) compared 
with the other groups (figure 2); however, in comparison with 
the presenilin-1 and TDP43A groups, the differences were very 
small and did not survive correction for multiple comparisons.
The presenilin-1 group had greater volume loss in the thal-
amus bilaterally compared with the early-onset AD group 
(p<0.001 uncorrected), and around the cingulate gyrus in 
comparison with both the early-onset and late-onset AD group 
(p<0.05 FWE) and the DLB group (p<0.05 FWE). In compar-
ison with the FTLD groups, greater volume loss was observed 
in more posterior brain regions, also around the cingulate gyrus 
when contrasted with the 3-repeat-tau (p<0.05 FWE) and 
TDP43C groups (p<0.05 FWE), and around the superior pari-
etal lobule when contrasted with the 4-repeat-tau (p<0.05 FWE) 
and TDP43A groups (p<0.001 uncorrected).
The late-onset AD group also demonstrated significant volume 
loss in parietal and occipital cortical regions in comparison with 
DLB, tau and TDP43C groups (p<0.001 uncorrected). In addi-
tion, the associated effect size maps also highlighted smaller 
hippocampal volumes in all but the 3-repeat-tau comparison 
and the left hippocampus when compared with the TDP43C 
pathology group.
On the basis of the effect size maps, the DLB group demon-
strated greater volume loss in the region of the precentral and 
postcentral gyri, the precuneus and the cerebellum in compar-
ison with all other groups; however, none of these differences 
remained after correction for multiple comparisons.
The FTLD pathology groups demonstrated greater and 
extensive volume loss in frontal and temporal lobe regions in 
comparison with all other groups (figures 3 and 4). The 3-repeat 
tau group had significantly smaller grey matter volume in the 
frontal cortex in comparison with all other pathology groups 
(p<0.05 FWE, figures 3 and 4), particularly around the piri-
form and insular cortex, and around the anterior cingulate gyrus 
except in comparison with the 4-repeat-tau and TDP43A groups. 
The 4-repeat-tau group also had significant volume loss around 
the anterior cingulate, although this did not survive correction 
for multiple comparisons for all contrasts. The TDP43A group 
demonstrated greater volume loss around the lateral orbi-
to-frontal and inferior-frontal gyrus in comparison with the DLB 
and TDP43C groups, while in comparison with the late-onset 
Figure 4 Grey matter volume differences based on pairwise comparison with the FTLD pathology groups. The axial image slices are effect size maps and 
the label shown above each map indicates the group comparison. Text colour relates to image colour, with the coloured regions in the image representing 
greater volume loss in the associated group, and brain slices chosen to represent the most interesting findings. The statistical parametric map slices to 
the left and right of the effect size maps represent the forward and reverse contrasts associated with each group comparison, with brain slices displayed 
based on peak voxel location. Greater volume loss in the blue group is shown on the left, with the red group shown on the right statistical parametric 
map. DLB, dementia with Lewy bodies; FTLD, frontotemporal lobar degeneration; FWE, familywise error rate; L, left; R, right; UNC, uncorrected (for multiple 
comparisons).
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AD group, volume differences were localised to the left ante-
rior striatum (p<0.05 FWE). As expected, the TDP43C group 
showed extensive grey matter volume loss in the left anterior 
temporal lobe in comparison with all other pathology groups, 
extending into the right anterior temporal lobe in comparison 
with the late-onset AD group, the DLB and the 4-repeat-tau 
groups (p<0.05 FWE).
While it is only possible to show a few representative brain 
slices in each figure (figures 3–5), unthresholded statistical 
maps have been uploaded to the NeuroVault repository (http:// 
neurovault. org/ collections/ ADHMHOPN/) to allow for further 
inspection of grey matter and white matter volume differences 
throughout the brain for each comparison.
DISCUSSION
To our knowledge, this is the largest VBM imaging study to 
investigate brain volume differences between different patholog-
ically proven dementias, allowing for a comprehensive assess-
ment of differences between pathology groups and healthy 
controls, as well as direct comparisons between pathology 
groups (see table 1 for a review of the existing literature). Care 
was taken to age-match the patient groups to controls in order to 
reduce the influence of age-related volume loss, and results were 
also statistically adjusted for age (at time of scan), sex and total 
intracranial volume,16 as well as MRI field strength and site. 
Individuals with AD pathology were also separated into autoso-
mal-dominant presenilin-1 mutation carriers, early-onset (before 
65 years) and late-onset groups to investigate patterns of atrophy 
reported in relation to these often quite distinct disease pheno-
types.17 18 Individuals with FTLD-tau were stratified based on 
the predominant tau isoform found at post-mortem. In compar-
ison with healthy controls, results are reported based on a strict 
statistical threshold, controlling the FWE rate at a significance 
level of p<0.001 (ie, fewer than 1 in 1000 statistical maps would 
have any false-positive voxels).
AD pathology was associated with extensive volume loss, 
particularly in temporoparietal regions (figure 1), in keeping 
with the known locus of AD pathology. However, the early-
onset group demonstrated more extensive parietal lobe atrophy, 
whereas the late-onset group demonstrated more focal medial 
temporal lobe volume loss (figure 1). In the direct comparison 
between the two groups, only volume differences in the left pari-
etal lobe were statistically significant. This confirms previous 
reports from smaller studies based on clinical diagnosis.19 
This, in turn, has clinical implications, confirming that, despite 
research criteria that focus on the presence/absence of hippo-
campal atrophy for the diagnosis of AD, this may not be a strong 
feature in patients with early-onset disease.
The late-onset AD group also demonstrated smaller parietal/
occipital lobe volumes in comparison with the DLB, FTLD-tau 
and TDP43C groups (figures 2 and 3), in keeping with reported 
disruption to the brain’s default mode network due to AD 
pathology.20 This was also evident in the other Alzheimer’s 
pathology groups, with additional involvement of the anterior 
cingulate cortex.
In comparison with healthy controls and the early-onset AD 
group, the autosomal-dominant mutation carriers demonstrated 
focal volume loss in thalamic regions, which has recently been 
described as a potentially critical hub to explain the symptom-
ology of the disease.21 Increased volume loss in this region has 
Figure 5 White matter volume differences based on pairwise comparison with the appropriate age-matched control group.All results are shown at 
afamilywise errorcorrected significance level ofp<0.05.Brain slices are displayed based on peak voxel location.DLB, dementia with Lewy bodies; EOAD, 
early-onset Alzheimer's disease; FTLD, frontotemporal lobar degeneration; FWE, familywise error rate; L, left; LOAD, late-onset Alzheimer's disease; OC, older 
controls; PS1, presenilin-1; R, right; YC, younger controls.
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previously been reported in presymptomatic and symptomatic 
presenilin-1 mutation carriers compared with controls18 22 but 
not between presenilin-1 and sporadic early-onset AD as shown 
here.
Similar to the other neurodegenerative pathologies included 
in this study, patients with primary DLB pathology demonstrated 
global volume loss in comparison with the age-matched controls 
(see effect size map in figure 2). However, when contrasted 
directly with the other groups, the effect was much smaller, with 
relative sparing of the hippocampi, consistent with previous 
reports.23–26 Statistical significance was reached in the region 
of the amygdalae bilaterally. However, volume reduction in this 
region also correlates with neurofibrillary tangle burden, which 
may explain why significant differences were not seen in the 
direct comparison of DLB with AD.23 27 When compared with 
the other pathologies, DLB was associated with reduced grey 
matter volume in the region of the precentral and postcentral 
gyri. Similar findings have been reported in Parkinson’s disease, 
suggesting that atrophy in this region may be a feature of Lewy 
body pathology more generally.28 The DLB group also demon-
strated occipital lobe volume loss, in keeping with previous 
reports of occipital hypometabolism revealed using fluorode-
oxyglucose-positron emission tomography.23 29 While primary 
motor, sensory and occipital cortex changes are often considered 
relatively spared in most degenerative dementias, these results 
suggest that there may be subtle but detectable changes in these 
regions in DLB; this, in turn, provides clear hypotheses that can 
be tested using more advanced MRI techniques.
There was considerable overlap in the pattern of frontal 
lobe atrophy between the FTLD-tau groups and the TDP43A 
group,30 31 particularly in the ventrolateral prefrontal cortex. 
However, the TDP43A pathology group appeared to have a 
more symmetrical presentation with greater parietal extension, 
while the left hemisphere was more affected in the 3-repeat-tau 
and 4-repeat-tau groups. The TDP43C group, which predomi-
nantly manifests clinically as semantic dementia, had extensive 
left anterior temporal lobe atrophy as previously reported in 
other studies.32 33
Although this study benefits from an unprecedented sample 
size of ante-mortem imaging acquired in patients with patho-
logical confirmation of their diagnosis, analysis using the most 
advanced SPM software and, where possible, strict statistical 
thresholding, it has a number of limitations. Including data 
from multiple sites increases the sample size, the power to 
detect statistical differences between groups and importantly 
the generalizability of the findings, but it also introduces poten-
tial confounds relating to the different MRI scanners and pulse 
sequences used to acquire the images. To account for this, 
magnetic field strength, which is likely to be the most signifi-
cant source of variability,34 was included along with acquisition 
site as factors in the model. Although the overall sample size is 
larger than those previously reported in the literature, sample 
sizes were insufficient to stratify beyond the primary patholog-
ical diagnosis, noting that in practice many patients will have 
multiple neurodegenerative pathologies of varying extent and 
severity, and concomitant vascular disease, all of which may 
influence developing patterns of brain volume loss.35 36 In addi-
tion, control subjects were not pathologically confirmed; there-
fore, we cannot rule out presymptomatic pathology in this group, 
which may reduce the power in comparing the pathology groups 
with controls. However, this does not affect the more clinically 
relevant between-pathology group comparisons. Although not 
quite reaching statistical significance (p=0.05), there was a 
lower proportion of men included in the younger control group 
than the other groups; however, as all subjects were included 
in a single model, sex differences are adjusted for using precise 
estimates from the total number of men and women included 
in the model. Finally, as with many research studies, there may 
be selection bias in the patients included in this cohort: those 
patients with memory and language led presentations, and those 
with familial forms of dementia, are more likely to take part 
in research, including brain donation, than patients with more 
challenging behavioural problems, for example. This may affect 
the representation of pathologies in this cohort and reduce how 
well the results generalise to the wider population.
Although the advent of molecular imaging provides a direct 
means of identifying underlying pathology during life,37 38 
the ability to use information from widely available, routinely 
acquired, noninvasive MRI scans is currently much more appli-
cable in clinical practice; and structural MRI continues to be 
the most widely used surrogate marker of neurodegeneration, 
reflected by its inclusion in a recently proposed classification 
scheme,39 and its continued inclusion in research diagnostic 
guidelines.40 Ultimately, however, it is only by using robust meth-
odologies to compare in vivo tests with post-mortem confirma-
tion in large and varied data sets that the diagnostic utility of 
any dementia biomarker can be assessed. The data from this 
study—which have been uploaded to the NeuroVault repository 
for independent scrutiny—provide much needed validation of 
the regions of the brain where neurodegenerative pathologies 
are detectable during life, and as such may have greater utility 
in clinical decision making. In addition, this study highlights 
where evidence is lacking and demonstrates that voxelwise brain 
mapping techniques applied to well-defined groups can reveal 
potentially overlooked regions that warrant further investigation 
as imaging biomarkers.
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